Case Study

The Challenge: A Critical Leadership Void at a Pivotal Transition

An emerging, venture-backed oncology company in the Boston biotech hub had developed a promising, novel therapeutic candidate for rare hematological malignancies. As they finalized their IND-enabling studies, they faced a complex strategic obstacle: they did not have an in-house Chief Medical Officer.

To transition from laboratory research to active clinical trials, they urgently needed a veteran physician leader who could:

1. 1. Provide immediate clinical development strategy and protocol design for a First-in-Human (FIH) trial.
   2. Represent the organization as a credible peer to world-renowned Key Opinion Leaders (KOLs), clinical investigators, and institutional investors.
   3. Establish a functional internal team structure to support clinical trial operations, medical monitoring, and data management.

Finding a full-time, permanent CMO with deep hematological-oncology specialization and small-biotech experience can take 6 to 12 months. More importantly, the company’s early-stage budget made a full-time C-suite hire economically inefficient. They needed elite, strategic medical oversight, but only on a fractional basis.

The Solution: BioPoint’s High-Touch, Agile Fractional Network

BioPoint was engaged to deliver an immediate, specialized leadership solution. Leveraging our deep, pre-vetted network of executive biopharma consultants, we identified and onboarded a Board-Certified Physician with a subspecialty in Hematology and Oncology.

The Consultant’s Profile:

• • • • Experience: Over 20 years of drug development leadership, with a proven track record of taking multiple oncology assets from preclinical phases through to global commercialization.
      • Track Record: Significant experience leading small, agile biotech teams and establishing clinical operations infrastructure from the ground up.
      • Network: Strong existing relationships with top-tier academic investigators, oncologists, and health authority reviewers.

Engagement Execution:

To maximize capital efficiency, BioPoint structured the engagement as a flexible, part-time model:

• • • • The Initial Phase: The consultant integrated seamlessly as the fractional CMO at 20 hours per week, focusing immediately on protocol finalization, investigator site selection, and establishing the clinical trial’s Scientific Advisory Board.
      • Dynamic Resource Scaling: As major regulatory and operational milestones approached (such as IND submission and site initiation visits), the consultant temporarily ramped up hours to support the volume of work.
      • Organizational Architecture: Operating inside the client’s infrastructure, the fractional CMO collaborated with the executive leadership team to design, recruit, and onboard a permanent, in-house clinical support team to sustain long-term operations.

The Impact: Getting to the Clinic and Beyond

BioPoint’s fractional CMO provided the strategic vision and tactical execution necessary to guide the biotech through its transition seamlessly.

Key Milestones Achieved:

• • • • Successful Clinical Entry: The fractional CMO successfully led the clinical design and strategy, culminating in IND clearance and the official initiation of the FIH study.
      • Dosing of the First Patient: Under the consultant’s leadership, site activations and patient enrollment were streamlined, leading to the successful dosing of the first patient within the targeted timeline.
      • Elite KOL & Stakeholder Engagement: The consultant effectively represented the company at major industry symposia, building strong relationships with critical investigators and presenting clinical data to key stakeholders and potential future investors with absolute credibility.
      • Internal Team Buildout: Working closely with the client, the consultant successfully built out the internal clinical operations and safety monitoring team, ensuring a smooth transition of daily responsibilities as the trial scaled.

The Takeaway: Driving Strategic Value Over Volume

By choosing BioPoint’s fractional executive service, this rare oncology sponsor proved that emerging biotechs do not have to compromise on leadership quality due to budget constraints.

Through this agile model, they secured:

• • • • Instant credibility with investigators and KOLs.
      • Expert clinical direction during their most vulnerable phase.
      • Significant cost savings by avoiding a premature executive search and full-time compensation package.